Clinical trials: Left Atrial Appendage Closure
Atrial Fibrillation
Left Atrial Appendage Closure in Combination With Catheter Ablation
This study is a prospective cohort study aimed at investigating the efficacy and safety of left atrial appendage closure in combination with catheter ablation in patients with atrial fibrillation.
- Trial name
- LAACablation (NCT03788941)
- Testing
- left atrial appendage closure and catheter ablation
- Where
- China
- Volunteers
- 1,200 people, healthy volunteers welcome
- Sponsor
- Xinhua Hospital, Shanghai Jiao Tong University School of Medicine
Aortic Valve Disorder
Combined Transcatheter Aortic Valve Implantation and Percutaneous Closure of the Left Atrial Appendage
Atrial fibrillation (AF) is a common comorbidity of patients candidates to transcatheter aortic valve implantation (TAVI). The management of chronic oral anticoagulation (OAC) for the prevention of ischemic stroke is very…
- Trial name
- TAVI-LAAC (NCT02678871)
- Testing
- Lotus or ACURATE neo Heart valve system (or subsequent CE marked iterations), WATCHMAN
- Where
- 6 sites in Germany, Italy and 2 more
- Volunteers
- 15 people, healthy volunteers welcome
- Sponsor
- Insel Gruppe AG, University Hospital Bern
Non-valvular Atrial Fibrillation
Observe the Safety and Effectiveness of the WATCHMAN FLX™ for Subjects in Hong Kong
The primary objective of this study is to observe the safety and effectiveness of the WATCHMAN FLX™ Left Atrial Appendage Closure (LAAC) Device for subjects with non-valvular atrial fibrillation to reduce the risk of stroke in…
- Trial name
- NCT04096963
- Testing
- The WATCHMAN FLX Delivery System
- Where
- China
- Volunteers
- 50 people, healthy volunteers welcome
- Sponsor
- Boston Scientific Corporation
Left Atrial Appendage Closure, Thrombosis
Short-Term Anticoagulation Versus Antiplatelet Therapy for Preventing Device Thrombosis Following Left Atrial Appendage Closure
The objective of the study is to compare short-term (8 weeks) anticoagulation therapy (DOAC) vs. antiplatelet therapy for the prevention of device thrombosis following transcatheter LAAC.
- Conditions
- Left Atrial Appendage Closure, Thrombosis, Stroke, TIA
- Trial name
- ANDES (NCT03568890)
- Testing
- Rivaroxaban, dabigatran, apixaban, or edoxaban, Clopidogrel -75 mg/day, Low dose aspirin -80 to 125 mg/day-
- Where
- Canada
- Volunteers
- 510 people, healthy volunteers welcome
- Sponsor
- Centre de Recherche de l'Institut Universitaire de Cardiologie et de Pneumologie de Quebec